Most common symptoms of MF1*
Fatigue
Abdominal discomfort
Night sweats
Bone pain
Itching
Survey sponsored by Incyte Corporation.
Symptoms represent only those included in the MPN Symptom Assessment Form Total Symptom Scores (MPN-SAFTSS) and are not inclusive of all symptoms that were assessed in the MPN Landmark Survey.
*Symptoms were reported within the last 12 months prior to survey.1
Starting the conversation about MF symptoms
MF can place a substantial burden on patients. Common clinical manifestations include2:
Fever
Weight loss
Anemia
Leukoerythroblastosis
Pruritus3
Splenomegaly
Increased or decreased white blood cell levels
Bone marrow fibrosis
Other possible clinical presentations of MF include2:
- Hepatomegaly
- Lymphadenopathy
- Pleural effusion
- Osteosclerosis
- Periostitis
- Portal hypertension
- Ascites
- Nerve or spinal cord compression
- Hypertrophic osteoarthropathy
- Megakaryocytic dysplasia
Spleen and Symptom Brochure
This resource includes key information related to splenomegaly and symptom assessment in patients with MF, as well as insights by Ruben A. Mesa, MD, FACP
MF carries a symptom burden that affects the majority of patients4
Prevalence of MF-related symptoms at diagnosis4
of patients reported at least 2 MF-related symptoms at diagnosis
based on a retrospective chart review of 180 patients with MF†
†Retrospective observational study of symptom burden and splenomegaly in 180 patients with MF; data were collected at the time of diagnosis of MF in patients without splenomegaly (n=78) or at the time of detection of splenomegaly (n=102). In patients with splenomegaly, splenomegaly was most often recorded at the time of diagnosis (median time from MF diagnosis to reported splenomegaly was 1 day).4
MPN symptom burden impacts quality of life1
The MPN Landmark Survey was a large-scale survey of 813 patients with MPNs (MF, n=207) and assessed perceptions of overall disease burden, quality of life, activities of daily living, and work productivity.1
In the Landmark Survey,
of patients with MF reported reduced quality of life related to their condition1
This was true even for patients with low prognostic risk scores and with the lowest symptom severity.1
MF=myelofibrosis; MPN=myeloproliferative neoplasm.
References: 1. Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167. doi:10.1186/s12885-016-2208-2. 2. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233-245. 3. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17(9):2954-2970. 4. Mitra D, Kaye JA, Piecoro LT, et al. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. Cancer Med. 2013;2(6):889-898.